Transcatheter Bariatric Embolotherapy for Weight Reduction in Obesity

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00023884%3A_____%2F20%3A00008803" target="_blank" >RIV/00023884:_____/20:00008803 - isvavai.cz</a>
Result on the web
<a href="https://pubmed.ncbi.nlm.nih.gov/33183504/#affiliation-3" target="_blank" >https://pubmed.ncbi.nlm.nih.gov/33183504/#affiliation-3</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.jacc.2020.09.550" target="_blank" >10.1016/j.jacc.2020.09.550</a>

Result language
angličtina
Original language name
Transcatheter Bariatric Embolotherapy for Weight Reduction in Obesity
Original language description
Obesity is well-appreciated to result in poor cardiovascular and metabolic outcomes. Dietary and medical weight loss strategies are frequently unsuccessful and unsustainable. Bariatric surgery is quite effective, but is reserved for the most obese patients because of the associated intraoperative/post-operative risks. In preclinical and early clinical case series, a novel therapy, transcatheter bariatric embolotherapy (TBE) of the left gastric artery, has been reported to promote weight loss by reducing ghrelin, an appetite-stimulating hormone secreted from the gastric fundus.
Czech name
—
Czech description
—

Type
J<sub>imp</sub> - Article in a specialist periodical, which is included in the Web of Science database
CEP classification
—
OECD FORD branch
30201 - Cardiac and Cardiovascular systems

Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)